34 Slingluff CL, Petroni GR, Yamshchikov GV, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low- dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 2004;22:4474–85. 35 Sabbatini P , Tsuji T, Ferran L, et al. Phase I trial of overlapping long peptides from a tumor self- antigen and poly- ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 2012;18:6497–508. 36 Melssen MM, Petroni GR, Chianese- Bullock KA, et al. A multipeptide vaccine plus Toll- like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients. J Immunother Cancer 2019;7:163. 37 Melief CJM, van der Burg SH. Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008;8:351–60. 38 Rosario M, Bridgeman A, Quakkelaar ED, et al. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single- gene vaccines in macaques. Eur J Immunol 2010;40:1973–84. 39 Quakkelaar ED, Melief CJM. Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients. Adv Immunol 2012;114:77–106.